Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (81-90 of 218) with videos related to

Pageof 22
Sort By:
Molecular Cancer Therapeutics|April 19, 2014
Moguntinones--new selective inhibitors for the treatment of human colorectal cancerAnnett Maderer, Stanislav Plutizki, Jan-Peter Kramb, et al.
Onkologie|December 17, 2008
[Treatment of nonresectable liver metastases]Markus Moehler, Karsten Ridwelski, Meinolf Karthaus, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II studyAlexander Stein, Dirk Arnold, Peter C Thuss-Patience, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 4, 2016
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancerMarkus Moehler, Rolf Mahlberg, Volker Heinemann, et al.
Future Oncology (London, England)|May 17, 2021
A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancerMarkus Moehler, Maurice Michel, Alexander Stein, et al.
BMC Cancer|July 22, 2004
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancerAndreas Teufel, Silke Steinmann, Jürgen Siebler, et al.
Hepato-Gastroenterology|June 30, 2010
Does expression of receptor tyrosine kinases in gastric adenocarcinoma correlate with clinicopathological parameters?Daniel Drescher, Ines Gockel, Stephan Timm, et al.
Onkologie|June 24, 2009
[Diagnosis and treatment of liver metastases from primary colorectal tumour]Dirk Arnold, Ernst J Rummeny, Thomas Kirchner, et al.
Zeitschrift Fur Gastroenterologie|January 15, 2020
Markus Moehler, Thomas Langer, Tanja Bender, et al.
BMC Gastroenterology|February 5, 2025
Collagen turnover biomarkers to predict outcome of patients with biliary cancerLeonard Kaps, Muhammed A Genc, Markus Moehler, et al.
Pageof 22

Showing results (81-90 of 218) with videos related to

Sort By:
Pageof 22
Molecular Cancer Therapeutics|April 19, 2014
Moguntinones--new selective inhibitors for the treatment of human colorectal cancerAnnett Maderer, Stanislav Plutizki, Jan-Peter Kramb, et al.
Onkologie|December 17, 2008
[Treatment of nonresectable liver metastases]Markus Moehler, Karsten Ridwelski, Meinolf Karthaus, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II studyAlexander Stein, Dirk Arnold, Peter C Thuss-Patience, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 4, 2016
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancerMarkus Moehler, Rolf Mahlberg, Volker Heinemann, et al.
Future Oncology (London, England)|May 17, 2021
A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancerMarkus Moehler, Maurice Michel, Alexander Stein, et al.
BMC Cancer|July 22, 2004
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancerAndreas Teufel, Silke Steinmann, Jürgen Siebler, et al.
Hepato-Gastroenterology|June 30, 2010
Does expression of receptor tyrosine kinases in gastric adenocarcinoma correlate with clinicopathological parameters?Daniel Drescher, Ines Gockel, Stephan Timm, et al.
Onkologie|June 24, 2009
[Diagnosis and treatment of liver metastases from primary colorectal tumour]Dirk Arnold, Ernst J Rummeny, Thomas Kirchner, et al.
Zeitschrift Fur Gastroenterologie|January 15, 2020
Markus Moehler, Thomas Langer, Tanja Bender, et al.
BMC Gastroenterology|February 5, 2025
Collagen turnover biomarkers to predict outcome of patients with biliary cancerLeonard Kaps, Muhammed A Genc, Markus Moehler, et al.
Pageof 22